Acquisition / mergerNotableFiled on BSE ·

Dr. Lal PathLabs Q1 FY27 results, ₹5 interim dividend, Ghana and Neuome stake deals

Dr Lal Pathlabs · Healthcare Services

Arthneeti Research DeskPublished 1 min read
₹764 CrAcquisition / merger

Key highlights

  • Standalone revenue from operations INR 7,644 million and standalone profit for the period INR 1,659 million; consolidated profit INR 1,705 million for the quarter ended June 30, 2026.
  • Interim dividend of INR 5 per equity share (50% on face value INR 10), record date July 30, 2026.
  • Dr Lal PathLabs FZCO approved acquiring 80% of Sunshine Healthcare Limited, Ghana, for up to GHS 45.6 Mn (INR 380 Mn) in first tranche; Neuome 30% subscription up to INR 35 Mn.

Why it's rated notable: the year-on-year change is 27% (20% to 50%)

Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.

Original filing

The Record Date For The Purpose Of Payment Of Interim Dividend Shall Be July 30, 2026

Read the filing on BSE (PDF) →

Companies guiding to strong growth

Ranked by management's own guidance on revenue and margins — not by us.

Rossell Techsys

Aerospace & Defense

Revenue growth 40%+Margin up 2%+

Sign up free to see all 6 →

See full rankings

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

More from Dr Lal Pathlabs

Other acquisition / merger filings this fortnight

All acquisition / merger filings →

Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.